NASDAQ: LTRN · Life Sciences · 4 alerts · CIK 1763950
Share price
$0.3890Close, Nov 16
Market cap
$4.97M
Shares outstanding
12.78MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lantern Pharma Inc. filings on SEC EDGAR ↗
Lantern Pharma Inc. received a deficiency notice from Nasdaq on September 25, 2026, for failing to maintain a minimum market value of listed securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, or until March 24, 2027, to regain compliance by maintaining an MVLS of at least $35 million for 10 consecutive business days.
Lantern Pharma Inc. entered into a securities purchase agreement for a registered direct offering of 1,469,725 common shares and 2,200,000 pre-funded warrants at $1.09 per share. The offering raised approximately $4 million in gross proceeds, with a concurrent private placement of warrants that could provide an additional $4 million if fully exercised. The company intends to use the proceeds for working capital and general corporate purposes.
Lantern Pharma hosted a live webinar and filed a formal presentation deck (Exhibit 99.1) to discuss its Open-Medicine AI multi-agentic platform for drug development. The presentation highlights the company's AI-driven approach to drug discovery and development, specifically focusing on the Open-Medicine AI platform.
Lantern Pharma is hosting a live webinar and investor presentation to discuss the growth plan, development roadmap, and economics of its wholly owned subsidiary, Open-Medicine AI. The session will include a live demonstration of the multi-agentic AI platform's capabilities and an overview of the subscription and enterprise licensing model.